Cost and cost-effectiveness of increasing access to sterile syringes and needles as an HIV prevention intervention in the United States

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 18, Issue SUPPL., 1998, Pages

  Holtgrave, David R ^a,b   Pinkerton, Steven D ^a   Jones, T Stephen ^b   Lurie, Peter ^c   Vlahov, David ^d  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

AIDS; Bloodborne infections; Cost and cost benefit analysis; HIV; Injection drug use; Pharmacies; Prevention; Syringe exchange programs; Syringes

Indexed keywords

ARTICLE; COST; COST EFFECTIVENESS ANALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; NEEDLE; PHARMACY; PRIORITY JOURNAL; RISK MANAGEMENT; SYRINGE; UNITED STATES; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0032125142     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199802001-00022     Document Type: Article

References (24)

1. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. Am J Public Health 1996;86: 642-54.
2. Centers for Disease Control and Prevention. AIDS associated with injecting-drug use - United States, 1995. MMWK Morb Mortal Wkly Rep 1996;45:392-8.
3. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington DC: National Academy Press, 1995.
4. American Medical Association. A physician guide to HIV prevention. Chicago: American Medical Association, 1996.
5. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
6. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institute on Drug Abuse, Substance Abuse and Mental Health Services Administration. HIV prevention bulletin: medical advice for persons who inject illicit drugs. Atlanta: Centers for Disease Control, May 8, 1997.
7. Holtgrave DR, Quails NL, Graham JD. Economic evaluation of HIV prevention. Annu Rev Public Health 1996;17:467-88.
8. Kahn JG. Are NEPs cost-effective in preventing HIV infection? In: Lurie P, Reingold AL, eds. The public health impact of needle exchange programs in the United States and abroad. San Francisco: Institute for Health Policy Studies, University of California at San Francisco, 1993:475-509.
9. Kaplan EH. Economic analysis of needle exchange. AIDS 1996;9: 1113-9.
10. Bigg D. Syringe exchange programs will not be enough. [letter]. Int J Drug Policy 1995;6:292.
11. Centers for Disease Control and Prevention. Update: syringe exchange programs - United States, 1996. MMWR Morb Mortal Wkly Rep 1997;46:565-8.
12. Haddix AC, Teutsch SM, Shaffer PA, Dunet DO, eds. Prevention effectiveness: a guide to decision analysis and economic evaluation. New York: Oxford University Press, 1996.
13. Morgan MG, Henrion M. Uncertainty: a guide to dealing with uncertainty in quantitative risk and policy analysis. New York: Cambridge University Press, 1990.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
15. Lurie P, Gorsky R, Jones TS, Shomphe L. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S126-32.
16. Holtgrave DR, Pinkerton SD. Updates of cost of illness and quality of life estimates for use in economic evaluations of HIV prevention programs. J Acquir Immune Defic Syndr Hum Retrovirol 1997;16: 54-62.
17. Reitemeijer CA, Davidson AJ, Foster CT, Cohn DL. Cost of care for patients with human immunodeficiency virus infection. Arch Intern Med 1993;153:219-25.
18. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Atlanta: Centers for Disease Control, 1996:1-39.
19. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
20. Holtgrave DR, Kelly JA. Preventing HIV/AIDS among high-risk urban women: the cost-effectiveness of a behavioral group intervention. Am J Public Health 1996;86:1442-5.
21. Holtgrave DR, Kelly JA. The cost-effectiveness of an HIV prevention intervention for gay men. AIDS Behav 1997;1:173-180.
22. Pinkerton SD, Holtgrave DR, Valdiserri RO. Cost-effectiveness of HIV prevention skills training for men who have sex with men. AIDS 1997;11:347-57.
23. Gostin LO. The legal environment impeding access to sterile syringes and needles: the conflict between law enforcement and public health. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S60-70.
24. Weinstein B, Toce P, Katz D, Ryan LL. Peer education of pharmacists and supplying pharmacies with IDU packets to increase injection drug users' access to sterile syringes in Connecticut [letter]. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S146-7.